Angela M DeMichele, MD MSCE

faculty photo
Alan and Jill Miller Professor in Breast Cancer Excellence
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Description of Clinical Expertise

breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship

Selected Publications

Rocque GB, Williams CP, Andrews C, Childers TC, Wiseman KD, Gallagher K, Tung N, Balch A, Lawhon VM, Ingram SA, Brown T, Kaufmann T, Smith ML, DeMichele A, Wolff AC, Wagner L.: Patient perspectives on chemotherapy de-escalation in breast cancer. Cancer Medicine May 2021.

Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S.: Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Clinical Cancer Research Mar 2021.

Kaufmann TL, Getz KD, Hsu JY, Bennett AV, Takvorian SU, Kamal AH, DeMichele A: Identification of Patient-Reported Outcome Phenotypes Among Oncology Patients With Palliative Care Needs. JCO Oncology Practice Mar 2021.

DeMichele A, Cristofanilli M, Brufsky A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS.: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Research Mar 2021.

Huang A, Bange E, Han N, Wileyto EP, Kim J, Gouma S, Robinson J, Greenplate A, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman A, Ittner C, Kugler E, Baxter A, Weirick M, McAllister C, Babady NE, Kumar A, Widman A, Dewolf S, Boutemine S, Roberts C, Budzik K, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles J, Oldridge D, Wu J, Alanio C, Adamski S, Vella L, Kerr S, Cohen J, Oyer R, Massa R, Maillard I, Maxwell K, Maslak P, Vonderheide R, Wolchok JD, Hensley S, Wherry E, Meyer N, DeMichele A, Vardhana S, Mamtani R, Oniyide O, Agyekum R, Dunn T, Jones T, Giannini H, Garfall A, Reilly J.: CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Research Square Feb 2021.

McAndrew N, Bottalico L, Mesaros C, Blair I, Tsao P, Ganguly T, Song S, Gimotty P, Mao J, DeMichele : Effects of systemic inflammation on relapse in early breast cancer: Results from the Wellness After Breast Cancer II (WABC-II) Study. NPJ Breast Jan 2021.

Sun L, Sanjna S, Le A, Desai H, Doucette A, Gabriel P, Ritchie M, Rader D, Maillard I, Bange E, Huang A, Vonderheide RH, DeMichele A, Verma A, Mamtani R, Maxwell KN: Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients. JNCI Cancer Spectr . Jan 2021.

I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA: Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncology 6(9): 1355-1362, Sep 2020.

McAndrew NP, Dickson MA, Clark AS, Troxel AB, O'Hara MH, Colameco C, Gallager M, Gramlich K, Zafman K, Vaughn D, Schwartz GK, O'Dwyer PJ, DeMichele A: Early treatment-related neutropenia predicts response to palbociclib. British Journal of Cancer 123(6): 912-918, Sep 2020 Notes: In Press.

Paul MR, Pan TC, Pant DK, Shih NN, Chen Y, Harvey KL, Solomon A, Lieberman D, Morrissette JJ, Soucier-Ernst D, Goodman NG, Stavropoulos SW, Maxwell KN, Clark C, Belka GK, Feldman M, DeMichele A, Chodosh LA.: Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 130: 4252-4265, Aug 2020.

back to top
Last updated: 05/04/2021
The Trustees of the University of Pennsylvania